IDEAS home Printed from https://ideas.repec.org/p/oec/elsaad/4-en.html
   My bibliography  Save this paper

Survey of Pharmacoeconomic Assessment Activity in Eleven Countries

Author

Listed:
  • Michael Dickson
  • Jeremy Hurst
  • Stephane Jacobzone

Abstract

Policy-makers responsible for publicly-funded drug programmes face continual pressures between the demand to accommodate a steady stream of new and more effective drugs and the ongoing requirement to control costs. In the face of these pressures, a growing number of OECD countries are applying ‘pharmacoeconomic assessment’ (health technology assessment for drugs) - to new drugs to guide decisions about accepting such products for reimbursement under their public programme, or to inform negotiations about pricing. This paper provides an analytical overview of the developing practice of pharmacoeconomic assessment in eleven OECD countries. It looks at the objectives of the activity, some of its processes and some of its impacts. It does this by drawing on a literature review and on an exploratory survey of the activities of pharmacoeconomic agencies in the eleven countries. It also reviews briefly the state of pharmacoeconomic assessment in the United States. The main conclusions are as ... Les responsables des programmes et dispositifs assurant la couverture des frais pharmaceutiques à l'aide de fonds publics sont en permanence tiraillés entre une demande de prise en charge d'un flot incessant de médicaments nouveaux et plus efficaces et la nécessité constante d'une maîtrise des dépenses. Face à cette situation, un nombre croissant de pays de l'OCDE ont entrepris de soumettre les nouveaux médicaments à une "évaluation pharmacoéconomique" (évaluation des technologies de la santé appliquée aux médicaments) - pour fonder leur décision de déclarer ou non ces produits remboursables par leur dispositif public ou pour éclairer les négociations sur les prix. Le présent document donne une vue analytique d'ensemble de la pratique d'évaluation pharmacoéconomique, telle qu'elle commence à se développer dans onze pays de l'OCDE; Sont envisagés les objectifs de l'activité, quelques-unes des procédures mises en œuvre et certaines conséquences. Le rapport s'appuie sur une ...

Suggested Citation

  • Michael Dickson & Jeremy Hurst & Stephane Jacobzone, 2003. "Survey of Pharmacoeconomic Assessment Activity in Eleven Countries," OECD Health Working Papers 4, OECD Publishing.
    • Handle: RePEc:oec:elsaad:4-en
    DOI: 10.1787/678644556018
    as

    Download full text from publisher

    File URL: https://doi.org/10.1787/678644556018
    Download Restriction: no
    File URL: https://libkey.io/10.1787/678644556018?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wasem, Jürgen & Niebuhr, Dea & Greß, Stefan, 2005. "Marktzugang und Preisbildung auf Arzneimittelmärkten im internationalen Vergleich," IBES Diskussionsbeiträge 142, University of Duisburg-Essen, Institute of Business and Economic Studie (IBES).
    2. repec:ces:ifodic:v:4:y:2006:i:2:p:14567506 is not listed on IDEAS
    3. Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
    4. Panos Kanavos & Olivier Wouters & John S. F. Wright & Anthony J. G. Barron & Sara M. B. Shah & Corinna Klingler, 2017. "Convergence, Divergence and Hybridity: A Regulatory Governance Perspective on Health Technology Assessment in England and Germany," Global Policy, London School of Economics and Political Science, vol. 8, pages 69-75, March.
    5. repec:bla:glopol:v:8:y:2017:i:s2:p:69-75 is not listed on IDEAS
    6. Stefan Greß & Jürgen Wasem & Dea Niebuhr, 2006. "Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance," ifo DICE Report, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, vol. 4(02), pages 39-47, July.
    7. Christine M. McDonough & Tor D. Tosteson & Anna N. A. Tosteson & Alan M. Jette & Margaret R. Grove & James N. Weinstein, 2011. "A Longitudinal Comparison of 5 Preference-Weighted Health State Classification Systems in Persons with Intervertebral Disk Herniation," Medical Decision Making, , vol. 31(2), pages 270-280, March.
    8. García-Alonso, M. D. C. & Mariñoso, B. G., 2005. "The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations," Working Papers 05/02, Department of Economics, City University London.
    9. Christine McDonough & Anna Tosteson, 2007. "Measuring Preferences for Cost-Utility Analysis," PharmacoEconomics, Springer, vol. 25(2), pages 93-106, February.
    10. Klingler, Corinna & Shah, Sara M.B. & Barron, Anthony J.G. & Wright, John S.F., 2013. "Regulatory space and the contextual mediation of common functional pressures: Analyzing the factors that led to the German Efficiency Frontier approach," Health Policy, Elsevier, vol. 109(3), pages 270-280.
    11. Stefan Greß & Jürgen Wasem & Dea Niebuhr, 2006. "Pricing and Reimbursement of Prescription Drugs in German Social Health Insurance," ifo DICE Report, ifo Institute - Leibniz Institute for Economic Research at the University of Munich, vol. 4(2), pages 39-47, 07.
    12. Christine de Mazières & Valérie Paris, 2004. "La régulation de l’industrie pharmaceutique," Revue d'Économie Financière, Programme National Persée, vol. 76(3), pages 241-265.

    More about this item

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oec:elsaad:4-en. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/eloecfr.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.